Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (GB:0L35)
LSE:0L35
Holding GB:0L35?
Track your performance easily
See the Price Targets and Ratings of:
0L35 Analyst Ratings
Strong Buy
14 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0L35 Stock 12 Month Forecast
Average Price Target
$195.20
▲(56.75% Upside)
| Highest Price Target$220.00 | Average Price Target$195.20 | Lowest Price Target$152.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
Reiterated
09/23/24
Cantor Fitzgerald
Reiterated
09/20/24
RBC Capital
Assigned
09/19/24
BMO Capital
Reiterated
09/11/24
Evercore ISI
Reiterated
08/12/24
Piper Sandler
Assigned
08/09/24
Oppenheimer
Reiterated
08/08/24
Barclays
Reiterated
08/08/24
Citi
Reiterated
08/08/24
Bank of America Securities
Reiterated
08/08/24
Morgan Stanley
$200
Buy
60.61%
Upside
Reiterated
08/08/24
Analysts' Top Healthcare Picks: Xtant Medical Holdings (XTNT), Tandem Diabetes Care (TNDM)
Needham
$235→$205
Buy
64.62%
Upside
Reiterated
08/08/24
Sarepta Therapeutics: A Buy Rating Amidst Forecasted Sales Acceleration and Strong Product Demand
Robert W. Baird
$200
Buy
60.61%
Upside
Reiterated
08/08/24
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Sarepta Therapeutics (NASDAQ: SRPT) and Intra-Cellular Therapies (NASDAQ: ITCI)
Leerink Partners
$230→$220
Buy
76.67%
Upside
Reiterated
08/07/24
Buy Rating Affirmed for Sarepta Therapeutics Amid Positive Revenue Outlook and Strong Pipeline Potential
J.P. Morgan
―
Buy
―
Reiterated
08/07/24
Maintaining Buy on Sarepta Therapeutics Amid Long-Term Growth Prospects and Overweight Rating for Elevidys
Best Analysts Covering Sarepta Therapeutics
Which Analyst Should I Follow If I Want to Buy GB:0L35 and Sell After:
1 Month
xxx
Success Rate
32/48 ratings generated profit
Average Return
+3.86%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.86% per trade.
3 Months
xxx
Success Rate
16/26 ratings generated profit
Average Return
+9.35%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +9.35% per trade.
1 Year
2 Years
xxx
Success Rate
16/19 ratings generated profit
Average Return
+17.36%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 84.21% of your transactions generating a profit, with an average return of +17.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0L35 Analyst Recommendation Trends
Rating
May 24
Jun 24
Jul 24
Aug 24
Sep 24
Strong Buy
1
2
2
7
8
Buy
28
48
48
40
18
Hold
5
7
7
6
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
34
57
57
53
29
Each month's total comprises the sum of three months' worth of ratings.
0L35 Financial Forecast
0L35 Stock Forecast FAQ
What is GB:0L35’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is $195.20.
What is GB:0L35’s upside potential, based on the analysts’ average price target?
Sarepta Therapeutics has 56.75% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Sarepta Therapeutics a Buy, Sell or Hold?
Sarepta Therapeutics has a consensus rating of Strong Buy, which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.
What is Sarepta Therapeutics’s share price target?
The average share price target for Sarepta Therapeutics is $195.20. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $220.00 ,and the lowest forecast is $152.00. The average share price target represents 56.75% Increase from the current price of $124.526.
The highest analyst share price target is $220.00 ,and the lowest forecast is $152.00. The average share price target represents 56.75% Increase from the current price of $124.526.
What do analysts say about Sarepta Therapeutics?
Sarepta Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of Sarepta Therapeutics?
To buy shares of GB:0L35, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.